OLMA
Olema Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company based in San Francisco that develops targeted therapies for women's cancers, especially breast cancer. Its lead drug candidate, palazestrant (OP-1250), is an oral pill designed to block the estrogen receptor that fuels many breast tumors, offering patients a daily-at-home option instead of an injection. Founded in 2016, the company went public in 2020 to fund its clinical trials.
CUSIP: 68062P106HealthcareUS1 holder
Recent Activity
2026Q1
1 sell
-15.2K shares
-15.2K shares
Loading more activity...